AbbVie reported $17.4B in Sales Revenues for its fiscal quarter ending in September of 2026.





Sales Change Date
AbbVie USD 17.4B 410M Sep/2026
Abbott USD 13.01B 423M Sep/2026
ALKERMES USD 480.13M 15.88M Sep/2026
Amgen USD 10.4B 300M Sep/2026
AstraZeneca USD 16.21B 830M Sep/2026
Biogen USD 2.8B 60M Sep/2026
BioMarin Pharmaceutical USD 1.03B 40M Sep/2026
Bristol-Myers Squibb USD 13.07B 100M Sep/2026
Coherus Biosciences USD 12.75M 1.18M Dec/2025
Eisai JPY 235.63B 1.3B Sep/2026
Eli Lilly USD 24.4B 1.43B Sep/2026
Gilead Sciences USD 8.3B 500M Sep/2026
GlaxoSmithKline GBP 8.89B 480M Sep/2026
J&J USD 25.4B 89M Sep/2026
Medtronic USD 9.8B 0 Jun/2026
Merck USD 18.1B 1.5B Sep/2026
Neurocrine Biosciences USD 1.12B 161M Sep/2026
Novartis USD 14.52B 112M Sep/2026
Pacira USD 176.65M 15.75M Sep/2026
Perrigo USD 989M 31M Sep/2026
Pfizer USD 16.6B 1.57B Sep/2026
Regeneron Pharmaceuticals USD 5.12B 830M Sep/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Sanofi EUR 14.44B 2.49B Sep/2026
UCB EUR 4.25B 764M Dec/2025
Ultragenyx Pharmaceutical USD 173M 41M Sep/2026
United Therapeutics USD 832.5M 49.2M Sep/2026
Vertex Pharmaceuticals USD 3.44B 110M Sep/2026
Zoetis USD 2.4B 100M Sep/2026